Ipsen joins clinical collaboration to evaluate cabozantinib (cabometyx®) plus atezolizumab in metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer

Regulatory news: ipsen (euronext: ipn; adr: ipsey), today announced it will join the exelixis and roche clinical collaboration and participate in the

AXDX Ratings Summary

AXDX Quant Ranking